Puma Biotechnology is a biopharmaceutical company that develops and commercializes cancer therapies, with its primary marketed product being NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved for HER2-positive breast cancer in both early-stage and metastatic settings. The company sells NERLYNX directly through a specialty sales force in the United States and through sub-licensing partnerships in more than 40 countries worldwide, generating revenue from product sales and royalties. Puma also holds a license to alisertib, an Aurora Kinase A inhibitor being developed for small cell lung cancer and hormone receptor-positive breast cancer, with revenue potential from regulatory milestones and tiered royalties on future net sales.